

IMI impact on paediatric medicine | 10 November 2021

Speaker bio



Claas Röhl

Member of the IMI Scientific Committee
President NF Kinder
President EUPATI Austria

After I received the diagnosis Neurofibromatosis Type 1 of my first child and after I was the main care giver during her 18 month of chemotherapy, my journey of becoming a patient advocate began. It was obvious that the circumstances for NF patients in Austria, but also all over the world, have to improve.

Participating in the EURORDIS summer school, the EURORDIS winter school, the EUPATI patient expert training course and also the ESO masterclass for cancer patient advocacy, helped me to learn about research and development of drugs, but also about patient advocacy. It also helped me to build an international network, to register at the EMA as a patient expert for Neurofibromatosis.

My goal is to optimize care for NF patients and contribute to NF research, by generating data with the NF communities all over the world, on patient priorities, unmet needs, patient relevant outcomes and by acting as a gateway to the patient community and assisting in communication and patient recruitment for clinical trials.